Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome

Liver International

Volumn 34, Issue 7, 2014, Pages

  Ginanni Corradini, Stefano ^a   Siciliano, Maria ^a   Parlati, Lucia ^a   Molinaro, Antonio ^a   Cantafora, Alfredo ^a   Poli, Edoardo ^a   Mennini, Gianluca ^a   Melandro, Fabio ^a   Vestri, Anna Rita ^a   Merli, Manuela ^a   Bianco, Paolo ^b   Corsi, Alessandro ^b   Toniutto, Pierluigi ^c   Bitetto, Davide ^c   Falleti, Edmondo ^c   Attili, Adolfo Francesco ^a   Berloco, Pasquale ^a   Rossi, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

Cholesterolemia; Cirrhosis; Graft survival; HMGCR; LDLR; Liver transplantation; NPC1L1; PCSK9; Serum cholesterol; SREBF2

Indexed keywords

CHOLESTEROL; CREATININE; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

BLOOD; FEMALE; HUMAN; ITALY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIOPERATIVE PERIOD; PROCEDURES; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

CHOLESTEROL; CREATININE; FEMALE; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIOPERATIVE PERIOD; PROPROTEIN CONVERTASES; PROSPECTIVE STUDIES; RECEPTORS, LDL; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84904498855     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12351     Document Type: Article

References (47)

1. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011; 54: 1297-306.
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
3. Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12: 1049-61.
4. Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: 2537-46.
5. Weismuller TJ, Fikatas P, Schmidt J, et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany-limitations of the 'sickest first'-concept. Transpl Int 2010; 24: 91-9.
6. Lisman T, van Leeuwen Y, Adelmeijer J, et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008; 28: 1344-51.
7. Habib A, Mihas AA, Abou-Assi SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol 2005; 3: 286-91.
8. Jiang M, Liu F, Xiong WJ, et al. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol 2010; 16: 1397-401.
9. Debonera F, Aldeguer X, Shen X, et al. Activation of interleukin-6/STAT3 and liver regeneration following transplantation. J Surg Res 2001; 96: 289-95.
10. Taki-Eldin A, Zhou L, Xie HY, Zheng SS. Liver regeneration after liver transplantation. Eur Surg Res 2012; 48: 139-53.
11. Albi E, Magni MV. The presence and the role of chromatin cholesterol in rat liver regeneration. J Hepatol 2002; 36: 395-400.
12. Albi E, Rossi G, Maraldi NM, et al. Involvement of nuclear phosphatidylinositol-dependent phospholipases C in cell cycle progression during rat liver regeneration. J Cell Physiol 2003; 197: 181-8.
13. Delgado-Coello B, Briones-Orta MA, Macías-Silva M, Mas-Oliva J. Cholesterol: recapitulation of its active role during liver regeneration. Liver Int 2011; 31: 1271-84.
14. Lo Sasso G, Celli N, Caboni M, et al. Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology 2010; 51: 1334-44.
15. Bollard ME, Contel NR, Ebbels TM, et al. NMR-based metabolic profiling identifies biomarkers of liver regeneration following partial hepatectomy in the rat. J Proteome Res 2010; 9: 59-69.
16. Dong XY, Tang SQ. Insulin-induced gene: a new regulator in lipid metabolism. Peptides 2010; 31: 2145-50.
17. Gong Y, Lee JN, Lee PC, et al. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab 2006; 3: 15-24.
18. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-8.
19. Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008; 49: 399-409.
20. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282: 18602-12.
21. Kurano M, Hara M, Tsuneyama K, et al. Modulation of lipid metabolism with the over-expression of NPC1L1 in mice liver. J Lipid Res 2012; 53: 2275-85.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
23. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010; 16: 943-9.
24. European Liver Transplant Registry. Available at http://www.eltr.org/
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
26. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: research0034.1-0034.11
27. Kim S, Kim T. Selection of optimal internal controls for gene expression profiling of liver disease. Biotechniques 2003; 35: 456-60.
28. Suzuki S, Teledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Transplantation 1993; 55: 1265-72.
29. Ravaioli M, Grazi GL, Dazzi A, et al. Survival benefit after liver transplantation: a single European center experience. Transplantation 2009; 88: 826-34.
30. Merrion RM. Current status and future of liver transplantation. Semin Liver Dis 2010; 30: 411-21.
31. Müllhaupt B, Dimitroulis D, Gerlach JT, Clavien PA. Hot topics in liver transplantation: organ allocation-extended criteria donor-living donor liver transplantation. J Hepatol 2008; 48(Suppl. 1): S58-67.
32. Durand F, Renz JF, Alkofer B, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694-707.
33. Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant 2011; 11: 1773-84.
34. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16.
35. Dai CY, Yeh ML, Huang CF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2013; doi: 10.1111/jgh.12313. [Epub ahead of print].
36. Chiarla C, Giovannini I, Giuliante F, et al. Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care 2010; 25: 361.e7-361.e12.
37. Conti A, Scala S, D'Agostino P, et al. Wide gene expression profiling of ischemia-reperfusion injury in human liver transplantation. Liver Transpl 2007; 13: 99-113.
38. Defamie V, Cursio R, Le Brigand K, et al. Gene expression profiling of human liver transplants identifies an early transcriptional signature associated with initial poor graft function. Am J Transplant 2008; 8: 1221-36.
39. Cao A, Wu M, Li H, Liu J. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res 2011; 52: 518-30.
40. Stopeck AT, Nicholson AC, Mancini FP, Hajjar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993; 268: 17489-94.
41. Chen YX, Ruan XZ, Huang AL, et al. Mechanisms of dysregulation of low-density lipoprotein receptor expression in HepG2 cells induced by inflammatory cytokines. Chin Med J (Engl) 2007; 120: 2185-90.
42. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008; 48: 646-54.
43. Howard TK, Klintmalm GB, Cofer JB, et al. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 1990; 49: 103-7.
44. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-9.
45. Pascher A, Neuhaus P. Biliary complications after deceased-donor orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13: 487-96.
46. Rasouli M, Mosavi-Mehr M, Tahmouri H. Liver denervation increases the levels of serum triglyceride and cholesterol via increases in the rate of VLDL secretion. Clin Res Hepatol Gastroenterol 2012; 36: 60-5.
47. Martínez-López E, Nuño-González P, Ruiz-Madrigal B, et al. Apolipoprotein AI and apolipoprotein E mRNA expression in peripheral white blood cells from patients with orthotopic liver transplantation. Liver Int 2007; 27: 930-7.